Specialty Pharmacy

Top news of the day from across the health care landscape.

Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

Top news of the day from across the health care landscape.

Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.

Older women with breast cancer who have a concurrent mental health condition are more likely to use opioids and have worse survival outcomes.

The effect of oral androgen signaling inhibitor therapies on patients with pre-existing cardiovascular disease may increase the risk of death.

Top news of the day from across the health care landscape.

An upcoming webinar by Trellis Rx on Wednesday, September 18, will offer a firsthand look into how to accelerate the growth of your specialty pharmacy program by building strong provider partnerships.

An in-house specialty pharmacy can provide significant financial gain for health systems by preventing revenue from being diverted to outside pharmacies.

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial.

Top news of the day from across the health care landscape.

Eli Lilly’s ixekizumab (Taltz) injection 80 mg/mL is now approved for the treatment of active ankylosing spondylitis.

Patients with progressive multiple sclerosis who were placed on the Wahls diet, which is high in fruits and vegetables, found to experience improved fatigue levels.

The findings showed a potential immune biomarker that may help predict patient response to standard-of-care treatment sorafenib for advanced liver cancer.

Top news of the day from across the health care landscape.

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.

Moderate physical activity may improve progression-free survival and reduce treatment-related adverse effects in patients undergoing chemotherapy for advanced colorectal cancer.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.

Top news of the day from across the health care landscape.

A recent study demonstrates the clinical benefit from the use of direct-acting antivirals for hepatitis C virus in patients with a history of liver cancer.

Top news of the day from across the health care landscape.

Novel process may identify cancer metastasis at an earlier stage when it may be easier to treat.